دورية أكاديمية
AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization.
| العنوان: | AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization. |
|---|---|
| المؤلفون: | Busse NC; Colorado Associates in Medical Physics, Denver, Colorado, USA., Al-Ghazi MSAL; University of California, Irvine, California, USA., Abi-Jaoudeh N; Department of Radiological Sciences, University of California, Irvine, California, USA., Alvarez D; Baptist Hospital, Miami Cancer Institute, Miami, Florida, USA., Ayan AS; Department of Radiation Oncology, Ohio State University, Columbus, Ohio, USA., Chen E; Department of Radiation Oncology, Cheshire Medical Center, Keene, New Hampshire, USA., Chuong MD; Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA., Dezarn WA; Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Enger SA; Department of Oncology, McGill University, Montreal, Canada., Graves SA; Department of Radiology, University of Iowa, Iowa City, Iowa, USA., Hobbs RF; Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland, USA., Jafari ME; Diagnostic Physics, Atlantic Health System, Morristown Medical Center, Morristown, New Jersey, USA., Kim SP; Medical Physics Unit, McGill University, Montreal, Canada., Maughan NM; Department of Radiation Oncology, Washington University in St. Louis, Saint Louis, Missouri, USA., Polemi AM; Department of Radiology, University of Virginia, Charlottesville, Virginia, USA., Stickel JR; Colorado Associates in Medical Physics, Denver, Colorado, USA. |
| المصدر: | Journal of applied clinical medical physics [J Appl Clin Med Phys] 2024 Feb; Vol. 25 (2), pp. e14157. Date of Electronic Publication: 2023 Oct 11. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley on behalf of American Association of Physicists in Medicine Country of Publication: United States NLM ID: 101089176 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-9914 (Electronic) Linking ISSN: 15269914 NLM ISO Abbreviation: J Appl Clin Med Phys Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Malden, MA : Wiley on behalf of American Association of Physicists in Medicine Original Publication: Reston, VA : American College of Medical Physics, c2000- |
| مواضيع طبية MeSH: | Liver Neoplasms*/radiotherapy , Embolization, Therapeutic*/methods, Humans ; Positron Emission Tomography Computed Tomography ; Microspheres ; Yttrium Radioisotopes/therapeutic use ; Physics |
| مستخلص: | Radioembolization using Yttrium-90 ( 90 Y) microspheres is widely used to treat primary and metastatic liver tumors. The present work provides minimum practice guidelines for establishing and supporting such a program. Medical physicists play a key role in patient and staff safety during these procedures. Products currently available are identified and their properties and suppliers summarized. Appropriateness for use is the domain of the treating physician. Patient work up starts with pre-treatment imaging. First, a mapping study using Technetium-99 m (Tc-99 m ) is carried out to quantify the lung shunt fraction (LSF) and to characterize the vascular supply of the liver. An MRI, CT, or a PET-CT scan is used to obtain information on the tumor burden. The tumor volume, LSF, tumor histology, and other pertinent patient characteristics are used to decide the type and quantity of 90 Y to be ordered. On the day of treatment, the appropriate dose is assayed using a dose calibrator with a calibration traceable to a national standard. In the treatment suite, the care team led by an interventional radiologist delivers the dose using real-time image guidance. The treatment suite is posted as a radioactive area during the procedure and staff wear radiation dosimeters. The treatment room, patient, and staff are surveyed post-procedure. The dose delivered to the patient is determined from the ratio of pre-treatment and residual waste exposure rate measurements. Establishing such a treatment modality is a major undertaking requiring an institutional radioactive materials license amendment complying with appropriate federal and state radiation regulations and appropriate staff training commensurate with their respective role and function in the planning and delivery of the procedure. Training, documentation, and areas for potential failure modes are identified and guidance is provided to ameliorate them. (© 2023 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.) |
| References: | Health Phys. 2012 Nov;103(5 Suppl 3):S204-8. (PMID: 23026974) J Nucl Med. 2017 Sep;58(Suppl 2):104S-111S. (PMID: 28864605) J Nucl Med. 2013 Sep;54(9):1557-63. (PMID: 23907758) J Nucl Med. 2016 May;57(5):665-71. (PMID: 26635340) Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1654-62. (PMID: 20422185) Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):451-461. (PMID: 30191875) EJNMMI Res. 2018 Jun 15;8(1):50. (PMID: 29904808) Gastroenterology. 2010 Jan;138(1):52-64. (PMID: 19766639) Cancer. 2008 Apr 1;112(7):1538-46. (PMID: 18260156) J Nucl Med. 2007 Dec;48(12):2080-6. (PMID: 18006608) Adv Radiat Oncol. 2020 Nov 24;6(2):100617. (PMID: 33912733) Quant Imaging Med Surg. 2020 Jan;10(1):160-170. (PMID: 31956539) Front Oncol. 2014 May 22;4:121. (PMID: 24904832) Ann Biomed Eng. 2020 May;48(5):1499-1510. (PMID: 32006268) Med Phys. 2017 Dec;44(12):6364-6376. (PMID: 28940483) Med Phys. 2011 Aug;38(8):4824-45. (PMID: 21928655) Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1393-406. (PMID: 21494856) Phys Med Biol. 2015 Mar 7;60(5):1945-64. (PMID: 25668639) Cancers (Basel). 2019 Jun 24;11(6):. (PMID: 31238514) PLoS One. 2014 Nov 04;9(11):e110401. (PMID: 25369020) J Vasc Interv Radiol. 2017 Mar;28(3):334-341. (PMID: 28109724) EJNMMI Phys. 2021 Jun 10;8(1):45. (PMID: 34114115) J Nucl Med. 2013 Nov;54(11):1890-5. (PMID: 24071510) Appl Radiat Isot. 2015 Mar;97:170-176. (PMID: 25579458) Med Phys. 2016 Oct;43(10):5779. (PMID: 27782730) Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1696. (PMID: 19618182) Med Phys. 2013 Aug;40(8):082504. (PMID: 23927349) Med Phys. 2016 Sep;43(9):5093. (PMID: 27587040) Cardiovasc Intervent Radiol. 2013 Dec;36(6):1536-1547. (PMID: 23435742) EJNMMI Res. 2018 Jan 22;8(1):7. (PMID: 29356993) J Nucl Med. 1999 Jun;40(6):1024-8. (PMID: 10452321) Hepatology. 2013 Dec;58(6):2188-97. (PMID: 23512791) PLoS One. 2013;8(2):e55742. (PMID: 23405207) Med Phys. 2019 Jan;46(1):229-237. (PMID: 30375655) IEEE Trans Med Imaging. 2009 Nov;28(11):1754-8. (PMID: 19884064) Radiology. 2017 Jan;282(1):281-288. (PMID: 27440733) Radiat Oncol J. 2021 Jun;39(2):113-121. (PMID: 34619828) Med Phys. 2013 Dec;40(12):122503. (PMID: 24320539) Eur J Nucl Med. 1996 Aug;23(8):947-52. (PMID: 8753684) EJNMMI Res. 2017 Nov 28;7(1):94. (PMID: 29185067) Clin Nucl Med. 2020 Feb;45(2):100-104. (PMID: 31876805) EJNMMI Phys. 2020 Dec 7;7(1):72. (PMID: 33284389) Med Phys. 2018 Oct;45(10):4744-4753. (PMID: 30179259) Tech Vasc Interv Radiol. 2019 Jun;22(2):63-69. (PMID: 31079712) J Appl Clin Med Phys. 2024 Feb;25(2):e14157. (PMID: 37820316) Tech Vasc Interv Radiol. 2019 Jun;22(2):70-73. (PMID: 31079713) Cardiovasc Intervent Radiol. 2021 Jan;44(1):21-35. (PMID: 32959085) Am J Clin Oncol. 2011 Jun;34(3):337-41. (PMID: 20921882) Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1494-500. (PMID: 19157721) Gastroenterology. 2016 Dec;151(6):1155-1163.e2. (PMID: 27575820) J Nucl Med. 2014 Aug;55(8):1317-22. (PMID: 24904111) Appl Radiat Isot. 2005 Aug;63(2):193-9. (PMID: 15963429) Lancet Oncol. 2017 Sep;18(9):1159-1171. (PMID: 28781171) Tech Vasc Interv Radiol. 2019 Jun;22(2):81-86. (PMID: 31079715) Semin Intervent Radiol. 2015 Dec;32(4):428-38. (PMID: 26622106) Pract Radiat Oncol. 2016 Nov - Dec;6(6):e299-e306. (PMID: 27155761) Clin Nucl Med. 2013 Dec;38(12):940-2. (PMID: 24212439) J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82. (PMID: 25099447) Phys Med. 2020 Dec;80:317-326. (PMID: 33248338) J Nucl Med. 2009 Mar;50(3):477-84. (PMID: 19258258) Cardiovasc Intervent Radiol. 2018 Dec;41(12):1857-1866. (PMID: 30006891) J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):46-51. (PMID: 10665249) J Gastrointest Oncol. 2017 Dec;8(6):1072-1078. (PMID: 29299369) AJR Am J Roentgenol. 2020 May;214(5):1158-1164. (PMID: 32130046) Phys Med. 2019 Dec;68:132-145. (PMID: 31785502) Phys Med Biol. 2012 Jun 21;57(12):3711-25. (PMID: 22617760) EJNMMI Phys. 2021 Oct 30;8(1):71. (PMID: 34716850) Lancet Gastroenterol Hepatol. 2021 Jan;6(1):2-3. (PMID: 33166498) EJNMMI Res. 2013 Jul 25;3(1):57. (PMID: 23885971) |
| فهرسة مساهمة: | Keywords: MPPG; Yttrium-90; brachytherapy; hepatic tumors; practice guideline; radioembolization |
| المشرفين على المادة: | 1K8M7UR6O1 (Yttrium-90) 0 (Yttrium Radioisotopes) |
| تواريخ الأحداث: | Date Created: 20231011 Date Completed: 20240214 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| مُعرف محوري في PubMed: | PMC10860558 |
| DOI: | 10.1002/acm2.14157 |
| PMID: | 37820316 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1526-9914 |
|---|---|
| DOI: | 10.1002/acm2.14157 |